The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - P2P | Acquired

Total Raised




About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals (NASDAQ: CLCD) aims to advance drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's pipeline includes lasmiditan, a treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans. Lasmiditan is a member of a drug class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans.

CoLucid Pharmaceuticals Headquarter Location

2520 Meridian Parkway Suite 400

Durham, North Carolina, 27713,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CoLucid Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CoLucid Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CoLucid Pharmaceuticals Patents

CoLucid Pharmaceuticals has filed 3 patents.

The 3 most popular patent topics include:

  • Benzamides
  • Fluoroarenes
  • Piperidines
patents chart

Application Date

Grant Date


Related Topics




Benzamides, Pyridines, Fluoroarenes, Piperidines, Glucocorticoids


Application Date


Grant Date



Related Topics

Benzamides, Pyridines, Fluoroarenes, Piperidines, Glucocorticoids



Latest CoLucid Pharmaceuticals News

Lilly's 1-drug migraine business gets support with new approval

Oct 11, 2019

Dive Brief: Eli Lilly on Friday won Food and Drug Administration approval for a migraine drug it acquired via a 2017 deal for CoLucid Pharmaceuticals, giving the Indianapolis pharma a partner treatment to its on-market therapy Emgality. Reyvow, as Lilly's drug will be sold, is approved to treat migraines as they develop, rather than to prevent the debilitating headaches from emerging in the first place, as Emgality is cleared to do. The FDA's OK of Reyvow adds to a stretch of drug development activity that's now resulted in four new treatments becoming available since last spring. Emgality, along with Novartis and Amgen's Aimovig and Teva's Ajovy, all belong to a class of preventive therapies known as CGRP inhibitors, while Reyvow works via a different biological mechanism. Dive Insight:​ Approval of Reyvow completes a circuitous development journey for a drug previously known as lasmiditan. Lilly licensed the then-experimental compound to CoLucid in 2005. Twelve years later, after the success of a Phase 3 study called SAMURAI, Lilly bought the company for $960 million and brought lasmiditan back into its pipeline. Now, Reyvow will be part of Lilly's efforts to build a therapeutic franchise in migraine, a condition estimated to affect as many as one in seven Americans. The pharma was third to market with its preventive offering Emgality (galcanezumab), following approvals of first Aimovig (erenumab) and then Ajovy (fremanezumab). Competitive jockeying for market share led all three companies to offer lengthy free drug programs following their respective launches — creating a showdown that's seen Amgen and Novartis retain an advantage in prescription numbers. Reyvow differs from those three drugs in several ways. It's designed to be used as an acute treatment, works by binding to serotonin (5-HT)1F receptors rather than calictonin gene-related peptides (CGRP) and is administered via tablet rather than injection. Testing in SAMURAI and another study called SPARTAN showed Reyvow resolved pain and lessened migraine symptoms like nausea or light sensitivity in more patients than placebo after two hours. The FDA approved Reyvow to treat migraine that presents with or without aura, the flashing lights or visual field phenomena that can sometimes accompany migraine attacks. Reyvow comes with a warning, however, of a risk of driving impairment. People taking the drug are advised not to drive or operate machinery for at least eight hours after taking Reyvow — a stipulation that could give some migraine sufferers pause before turning to the drug. Reyvow can also cause dizziness and sedation. As it's active in the central nervous system, Lilly studied the drug for abuse potential and found it to be associated with less drug liking than the sedative alprazolam, but more than placebo. The Drug Enforcement Administration is currently reviewing Reyvow for controlled substance classification, a typically 90-day process after which the treatment will be available in retail pharmacies. Lilly did not disclose a price at approval, saying cost information would be released nearer to market launch. Other companies, including BioHaven Pharmaceuticals and Allergan, are also advancing migraine therapies toward FDA review. Another potential entrant is Alder BioPharmaceuticals, which was acquired last month by Danish drugmaker Lundbeck for $1.95 billion. Recommended Reading:

  • When was CoLucid Pharmaceuticals founded?

    CoLucid Pharmaceuticals was founded in 2005.

  • Where is CoLucid Pharmaceuticals's headquarters?

    CoLucid Pharmaceuticals's headquarters is located at 2520 Meridian Parkway, Durham.

  • What is CoLucid Pharmaceuticals's latest funding round?

    CoLucid Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did CoLucid Pharmaceuticals raise?

    CoLucid Pharmaceuticals raised a total of $86.85M.

  • Who are the investors of CoLucid Pharmaceuticals?

    Investors of CoLucid Pharmaceuticals include Eli Lilly and Company, Domain Associates, Pappas Ventures, Triathlon Medical Venture Partners, Pearl Street Ventures and 8 more.

  • Who are CoLucid Pharmaceuticals's competitors?

    Competitors of CoLucid Pharmaceuticals include Tetraphase Pharmaceuticals, Viamet Pharmaceuticals, Anacor Pharmaceuticals, Alexza Pharmaceuticals, Pozen and 11 more.

You May Also Like

Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

Cervelo Pharmaceuticals

Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.

Ren Pharmaceuticals

Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals is interested in building collaborative research programs with academic institutions. Ren Pharmaceuticals is developing data and useful reagents (e.g. antibodies, recombinant proteins) for studying the biology of renalase. We are interested in in-licensing and developing products that leverage our core strengths and complement our existing portfolio. Products with applications in kidney disease and associative diseases (e.g. cardio-renal diseases) are key areas of interest.

Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

Funxional Therapeutics

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

Ancora Pharmaceuticals

Ancora Pharmaceuticals aims to enable synthetic carbohydrate-based product discovery and development utilizing its carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.